Spruce Biosciences, Inc. (SPRB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:56PM EST. Market open.
| Previous close | 3.4300 |
| Open | 3.2700 |
| Bid | 3.2200 x 800 |
| Ask | 3.2400 x 1100 |
| Day's range | 3.1000 - 3.3599 |
| 52-week range | 2.2500 - 28.4900 |
| Volume | |
| Avg. volume | 3,935,753 |
| Market cap | 75.779M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
SAN FRANCISCO, January 05, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer.
- Business Wire
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
SAN FRANCISCO, November 18, 2021--Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
- Business Wire
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
SAN FRANCISCO, November 15, 2021--Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
© 2022 Yahoo. All rights reserved.
